Can a Weight-Loss drug protect muscle and bone in seniors? new study aims to find out

NCT ID NCT06861439

Ongoing Disease control Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study is testing the drug tirzepatide (Zepbound) in 40 older adults with obesity to see how it affects body composition, bone density, and physical function over nine months. Participants take weekly injections, track their diet and activity, and attend regular check-ins. The goal is to understand if tirzepatide can help older adults lose fat without losing muscle or bone strength.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirzepatide (Zepbound)
What this could lead to: If successful, this could show that tirzepatide helps older adults lose fat while preserving muscle and bone, pointing toward safer weight management in this age group.
What could go wrong: This is a small pilot study with only 40 participants and no comparison group, so results may not apply broadly. Tirzepatide can cause side effects like nausea or digestive issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

muscular atrophy Obesity obesity disorder Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.